A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 29, 2026

Study Completion Date

November 29, 2026

Conditions

Pancreatic Neuroendocrine Tumor

Interventions

DRUG

Surufatinib

Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

DRUG

Placebo

Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Trial Locations (1)

Changhai Hospital, Shanghai

All Listed Sponsors

lead

Changhai Hospital

OTHER